We expect to generate operating losses for the foreseeable future, but intend to try to limit the extent of these losses by entering into co-development or collaboration agreements with one or more strategic partners, such as the license agreement entered into in September 2011 with a major Korean pharmaceutical company.
There is not a single company in this world that can predict the future and every company in the world has a potential to not make any revenue. That is mostly due to reasons that are beyond their control such as macroeconomic conditions, war conflicts, terror attacks, etc. Glad to see that Ampio is actually posting these and not try to deceive their investors.
All investors will read that entire document and not just one paragraph. This document in its entirely shows in honesty what the company is actually doing and how it progresses with their plans. This document has once again proven that Ampio is on track to deliver on their blockbuster drugs and that management is making the right decisions while taking minimal risks. So stop trying to deceive inexperienced investors and tell the truth for a change. It may help you in the long run.
Due to the time required to conduct clinical trials and obtain regulatory approval for any of our product candidates, we anticipate it will be some time before we generate substantial revenues, if ever.